Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

Ferris, Robert L., Blumenschein, George, Fayette, Jerome, Guigay, Joel, Colevas, A. Dimitrios, Licitra, Lisa, Harrington, Kevin, Kasper, Stefan, Vokes, Everett E., Even, Caroline, Worden, Francis, Saba, Nabil F., Iglesias Docampo, Lara C., Haddad, Robert, Rordorf, Tamara, Kiyota, Naomi, Tahara, Makoto, Monga, Manish, Lynch, Mark, Geese, William J., Kopit, Justin, Shaw, James W., Gillison, Maura L.·2016·New England Journal of Medicine
DOI 10.1056/nejmoa1602252

Cited by (1,010)

Items 1,001–1,010 of 1,010

  1. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: a systematic review
    Ghanizada, Mustafa, Jakobsen, Kathrine Kronberg, Grønhøj, Christian, von Buchwald, Christian · 2019 · Oral Oncology
  2. Viral Status and Efficacy of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis
    Ding, Ziniu, Dong, Zhaoru, Chen, Zhiqiang, Hong, Jianguo, Yan, Lunjie, Li, Haichao, Yao, Shengyu, Yan, Yuchuan, Yang, Yafei, Yang, Chuncheng et al. · 2021 · Frontiers in Immunology
  3. Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy
    Das, Satya, Ciombor, Kristen K., Haraldsdottir, Sigurdis, Pumpalova, Yoanna, Sahin, Ibrahim H., Pineda, G., Shyr, Yu, Lin, E.P., Hsu, Chih-Yuan, Chu, Shih-Kai et al. · 2020 · The Oncologist
  4. Impact of Antibiotic Therapy and Metabolic Parameters in Non-Small Cell Lung Cancer Patients Receiving Checkpoint Inhibitors
    Castello, Angelo, Rossi, Sabrina, Toschi, Luca, Lopci, Egesta · 2021 · Journal of Clinical Medicine
  5. A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA)
    Meindl-Beinker, Nadja M., Betge, Johannes, Gutting, Tobias, Burgermeister, Elke, Belle, Sebastian, Zhan, Tianzuo, Schulte, Nadine, Maenz, Martin, Ebert, Matthias P., Haertel, Nicolai · 2019 · BMC Cancer
  6. ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer
    Kyte, J. A., Røssevold, A., Falk, R. S., Naume, B. · 2020 · Journal of Translational Medicine
  7. Deep learning-based model for predicting progression in patients with head and neck squamous cell carcinoma
    Zhao, Zhen, Li, Yingli, Wu, Yuanqing, Chen, Rongrong · 2019 · Cancer Biomarkers
  8. The biology of combination immunotherapy in recurrent metastatic head and neck cancer
    Yuan, Xun, Yi, Ming, Zhang, Wei, Xu, Linping, Chu, Qian, Luo, Suxia, Wu, Kongming · 2021 · The International Journal of Biochemistry & Cell Biology
  9. Telomere Shortening in Peripheral Leukocytes Is Associated With Poor Survival in Cancer Patients Treated With Immune Checkpoint Inhibitor Therapy
    Rolles, Benjamin, Gorgulho, Joao, Tometten, Mareike, Roderburg, Christoph, Vieri, Margherita, Abels, Anne, Vucur, Mihael, Heymann, Felix, Tacke, Frank, Brümmendorf, Tim H. et al. · 2021 · Frontiers in Oncology
  10. Dynamic Changes in Circulating Tumor DNA During Immunotherapy for Head and Neck Cancer: SHIZUKU-HN Study
    Noji, Rika, Tohyama, Kohki, Nakamura, Shin, Naito, Takahiro, Oikawa, Yu, Kuroshima, Takeshi, Tomioka, Hirofumi, Michi, Yasuyuki, Ikeda, Sadakatsu, Asakage, Takahiro et al. · 2024 · International Journal of Molecular Sciences